News

Video

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

Author(s):

Aditya Bardia, MD, MPH

Dr. Aditya Bardia presents the findings of DESTINY-Breast06 (NCT04494425) in chemotherapy naive patients with HER2-low and HER2-ultra low metastatic breast cancer demonstrating progression-free survival of trastuzumab deruxtecan compared to chemotherapy treatment of physician’s choice.

Related Videos
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study
Intracranial Efficacy of Datopotamab Deruxtecan in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from Tropion-Lung05
Adrienne G. Waks, MD,
David Rimm, MD, PhD
This series features 2 KOLs
This series features 2 KOLs
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial
4 KOLs are featured in this series.
4 KOLs are featured in this series.
2 KOLs are featured in this program.
Related Content
Peter Forsyth, MD
June 26th 2024

Intrathecal Dendritic Cells Under Evaluation for Leptomeningeal Disease in TNBC and HER2+ Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jack Bailey
June 24th 2024

Trilaciclib Before Gemcitabine/Carboplatin Misses OS End Point in Metastatic TNBC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Mafalda Oliveira, MD, PhD, Vall d’Hebron University Hospital, senior clinical investigator, Vall d’Hebron Institute of Oncology’s Breast Cancer Group
June 20th 2024

European Commission Approves Capivasertib Plus Fulvestrant for ER+ Breast Cancer

Lauren E. Nye, MD, of University of Kansas Cancer Center
June 19th 2024

The Pursuit of Targeted Agents Broadens the HR+  Breast Cancer Treatment Paradigm